

Company profile

Sartorius is a leading international partner of the biopharma industry. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. Founded in 1870, Sartorius currently employs around 14,000 people in more than 35 countries. Its operational business is subdivided into two divisions: Bioprocess Solutions and Lab Products & Services.

Investment Highlights

- 1. Focus on the high-growth biopharma market
- 2. Broad and differentiating product offering
- 3. Strong global presence
- 4. High share of recurring business; significant market entry barriers
- 5. Proven track record with alliances and acquisitions;
- 6. High continuity with respect to customer base, employees and management


Key Figures

in millions of € unless otherwise specified	9M 2026	Δ in % 9M 2025	FY 2025	FY 2024	FY 2023	
Sales revenue (% Δ in const. fx)	2,737.2	+8.1 ¹ 6.9	2,610.5	3,538.1	3,380.7	3,395.7
Underlying EBITDA ²	827.8	+6.9	774.2	1,051.6	945.3	962.7
Underlying EBITDA margin ² in %	30.2	+0.5pp	29.7	29.7	28.0	28.3
Underlying net profit ³	259.8	+6.7	243.6	330.7	279.9	338.5
Underlying EPS per ordinary share ³ in €	3.76	+6.7	3.52	4.78	4.05	4.94
Underlying EPS per preference share ³ in €	3.77	+6.6	3.53	4.79	4.06	4.95
Equity ratio ⁴ in %	42.8	+3.1pp	39.7	39.8	38.6	28.3
Net debt to underlying EBITDA ^{2,5}	3.33	-	3.75	3.55	3.96	5.05


1 Operational sales growth before customer compensation for tariff surcharges
2 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
3 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
4 Equity in relation to the balance sheet total
5 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period

Figures are not audited or reviewed.

Sales Revenue by Division 2025



Sales Revenue by Region 2025



Guidance for fiscal year 2026 confirmed and partially refined

FY 2026 guidance	Sartorius Group	Bioprocess Solutions	Lab Products & Services
Sales revenue growth ¹ thereof MATTEK acquisition	~5% to ~9% ~0.3pp	~6% to ~10% -	~2% to ~6% ~1.5pp
Underlying EBITDA margin	slightly > 30%	slightly > 32%	slightly > 21% (prev.: slightly < 21%)

Where we expect to land within the range

Operational performance ²	around the midpoint	around the midpoint	around upper end (prev.: upper half)
incl. customer compensation refund application of €40m; €9m still outstanding	lower half of the range	lower half of the range	around upper end (prev.: around the midpoint)

Other KPIs

Capex ratio	~12% (prev.: ~12.5%)
Net debt / underlying EBITDA ³	slightly >3x

Due to the continued high dynamics and volatility across the life science industry, the forecast remains subject to greater uncertainty, which is reflected in the current guidance range. Potential further changes in U.S. tariffs are not included.
1 In constant currencies. 2 Operational sales growth before customer compensation for tariff surcharges, in constant currencies. 3 Excluding potential capital measures and/or acquisitions.

Division Strategy

Bioprocess Solutions

- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers’ production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and cell cultivation
- One of the widest portfolios in the industry; clear focus on single-use technologies such as filters, bags and cell culture media
- Continuous expansion through complementary acquisitions and targeted alliances

Lab Products & Services

- Premium provider of laboratory instruments, consumables and services for sample preparation and bioanalytic
- Leading international positions in laboratory balances, pipettes and lab consumables
- Outstanding brand reputation, strong product range and global services as the basis for further expansion of market share
- Extension of portfolio with complementary laboratory products through acquisitions and alliances

Facts about Preference Shares


Ticker symbol: SRT3
Ticker symbol Bloomberg: SRT3 GY
Ticker symbol Reuters: SATG_pe.DE
WKN | ISIN: 716 563 | DE0007165631

Facts about Ordinary Shares

Ticker symbol: SRT
Ticker symbol Bloomberg: SRT GY
Ticker symbol Reuters: SATG
WKN | ISIN: 716 560 | DE0007165607


Sartorius Shares in Comparison (indexed)

October 1, 2025, to September 30, 2026




Shareholder Structure: Ordinary Shares

September 30, 2026




Shareholder Structure: Preference Shares

September 30, 2026



The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. The legal disclosure requirements refer only to ordinary shares and not to non-voting preference shares.

Underlying Earnings per Share¹ in €



1 After non-controlling interest, adjusted for extraordinary items as well as amortization, and based on a normalized financial result and the normalized tax rate

Financial calendar

February 23, 2027
Full-year figures 2026 and 2026 Annual Report
April 15, 2027
Annual General Meeting

Disclaimer
This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbour risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

Sven Köpsel
Head of Corporate Communication & IR
Tel.: +49.551.308.9429
Email: sven.koepsel@sartorius.com

Petra Müller
Head of Investor Relations
Tel.: +49.551.308.6035
Email: petra.mueller2@sartorius.com